scholarly article | Q13442814 |
P356 | DOI | 10.1310/HCT1403-204 |
P698 | PubMed publication ID | 24144897 |
P50 | author | Federico Pulido | Q45357574 |
Joaquín Portilla | Q56449004 | ||
José Ramón Blanco | Q57423022 | ||
Julian Olalla | Q74043055 | ||
Alberto Romero Palacios | Q81565702 | ||
P2093 | author name string | Melchor Riera | |
Francisco Vera | |||
Pere Domingo | |||
Juan Luis Gómez-Sirvent | |||
Piedad Arazo | |||
Koldo Aguirrebengoa | |||
Ana María Caro-Murillo | |||
Enric Pedrol | |||
Manuel Angel Castaño | |||
Pedro Ferrer | |||
P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
A new equation to estimate glomerular filtration rate | Q24651973 | ||
Prevalence and factors associated with renal dysfunction among HIV-infected patients | Q30484533 | ||
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy | Q33565604 | ||
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy | Q33689432 | ||
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. | Q34289633 | ||
Neuropsychiatric complications of antiretroviral therapy | Q34565848 | ||
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o | Q35000905 | ||
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions | Q35088160 | ||
A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States | Q35872422 | ||
Treatment of HIV infection in the older patient | Q35917538 | ||
Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions | Q36342389 | ||
Medication compliance and persistence: terminology and definitions | Q37072950 | ||
Pharmacologic consideration for the use of antiretroviral agents in the elderly | Q37277510 | ||
Spectrum of chronic kidney disease in HIV-infected patients. | Q37396053 | ||
Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. | Q38958723 | ||
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study | Q42658845 | ||
The impact of gender and anchor drugs on TDF renal toxicity | Q42880491 | ||
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients | Q43044739 | ||
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France | Q43225383 | ||
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain | Q43237663 | ||
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City | Q45730280 | ||
Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy | Q45732541 | ||
Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. | Q46053873 | ||
Older age and the response to and tolerability of antiretroviral therapy | Q46177165 | ||
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy | Q46432681 | ||
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. | Q46900196 | ||
Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy | Q46943637 | ||
Premature age-related comorbidities among HIV-infected persons compared with the general population. | Q51000618 | ||
Chronic renal failure among HIV-1-infected patients. | Q51914547 | ||
P433 | issue | 5 | |
P921 | main subject | tenofovir | Q155954 |
emtricitabine | Q422604 | ||
P304 | page(s) | 204-215 | |
P577 | publication date | 2013-09-01 | |
P1433 | published in | HIV Clinical Trials | Q15756361 |
P1476 | title | Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study | |
P478 | volume | 14 |
Q41428022 | Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study | cites work | P2860 |
Search more.